Oncotarget

Research Papers:

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis

Tatsuo Kanda _, Shin Yasui, Masato Nakamura, Shingo Nakamoto, Koji Takahashi, Shuang Wu, Reina Sasaki, Yuki Haga, Sadahisa Ogasawara, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Yoshihiko Ooka, Eiichiro Suzuki, Tetsuhiro Chiba, Hitoshi Maruyama, Fumio Imazeki, Mitsuhiko Moriyama and Naoya Kato

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:11631-11637. https://doi.org/10.18632/oncotarget.24391

Metrics: PDF 1134 views  |   HTML 1780 views  |   ?  


Abstract

Tatsuo Kanda1,2, Shin Yasui2, Masato Nakamura2, Shingo Nakamoto2, Koji Takahashi2, Shuang Wu2, Reina Sasaki2, Yuki Haga2, Sadahisa Ogasawara2, Tomoko Saito2, Kazufumi Kobayashi2, Soichiro Kiyono2, Yoshihiko Ooka2, Eiichiro Suzuki2, Tetsuhiro Chiba2, Hitoshi Maruyama2, Fumio Imazeki2, Mitsuhiko Moriyama1 and Naoya Kato2

1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan

2Department of Gastroenterology, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan

Correspondence to:

Tatsuo Kanda, email: [email protected]

Keywords: hepatitis C virus; direct-acting antivirals; autoimmune hepatitis; primary biliary cholangitis; sustained virological response

Received: January 16, 2018     Accepted: January 30, 2018     Published: February 03, 2018

ABSTRACT

Background: Interferon-free treatment can achieve higher sustained virological response (SVR) rates, even in patients in whom hepatitis C virus (HCV) could not be eradicated in the interferon treatment era. Immune restoration in the liver is occasionally associated with HCV infection. We examined the safety and effects of interferon-free regimens on HCV patients with autoimmune liver diseases.

Results: All 7 HCV patients with autoimmune hepatitis (AIH) completed treatment and achieved SVR. Three patients took prednisolone (PSL) at baseline, and 3 did not take PSL during interferon-free treatment. In one HCV patient with AIH and cirrhosis, PSL were not administered at baseline, but she needed to take 40 mg/day PSL at week 8 for liver dysfunction. She also complained back pain and was diagnosed with vasospastic angina by coronary angiography at week 11. However, she completed interferon-free treatment. All 5 HCV patients with primary biliary cholangitis (PBC) completed treatment and achieved SVR. Three of these HCV patients with PBC were treated with UDCA during interferon-free treatment.

Conclusions: Interferon-free regimens could result in higher SVR rates in HCV patients with autoimmune liver diseases. As interferon-free treatment for HCV may have an effect on hepatic immunity and activity of the autoimmune liver diseases, careful attention should be paid to unexpected adverse events in their treatments.

Methods: Total 12 patients with HCV and autoimmune liver diseases [7 AIH and PBC], who were treated with interferon-free regimens, were retrospectively analyzed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24391